The science
The evidence for this product is unusually current, because both actives have trials published in the last few years. Oleyl adapalenate — marketed as Adapinoid — was tested in a 2024 prospective, double-blinded, randomized head-to-head trial in Skin Health and Disease against retinol, and the adapalene ester matched or exceeded retinol on measures of photoaging and texture with comparable tolerability, supporting its use as a cosmetic retinoid with adapalene-like activity. Adapalene itself is the retinoid with the strongest acne evidence at over-the-counter strength, and the ester's role here — 0.16 percent, converted by skin esterases — is to bring a fraction of that pore-clearing action into a cosmetic formula, which is the mechanistic basis for the brand's breakout-prone positioning.
Retinaldehyde's case is older and well established. A 2022 focused review in Advances in Therapy on topical retinoids in anti-aging treatment summarised the clinical evidence for conventional retinoids and their formulations, noting that retinaldehyde is converted to retinoic acid more directly than retinol, produces comparable improvements in photoaging to low-dose tretinoin in older trials, and is generally better tolerated than tretinoin at equivalent efficacy. A 2024 study in the Journal of Drugs in Dermatology on a retinaldehyde serum with firming peptides found improvements in skin texture and signs of photoaging with good tolerability over weeks of use — a different formulation, but supportive of retinal's efficacy-to-irritation profile at cosmetic doses.
What has not been studied is the combination. Retinal and adapalene act through overlapping retinoid receptors, and low individual doses of each are a plausible way to broaden effect without multiplying irritation, but no trial has tested 0.1 percent encapsulated retinal with 0.16 percent oleyl adapalenate together. The encapsulation — a calcium hydroxyapatite shell that slows release — is a recognised strategy for improving retinoid tolerability, and the vitamin E placed directly after the retinal is textbook stabilisation for a molecule that oxidises readily. The correct reading is a product whose two actives are individually well supported, combined on sound but untested reasoning.
References 3 ShowHide
- A prospective, double-blinded, randomized head-to-head clinical trial of topical adapinoid (oleyl adapalenate) versus retinol — Skin Health and Disease (2024)
- Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations — Advances in Therapy (2022)
- The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging — Journal of Drugs in Dermatology (2024)